These mechanistic insights were then corroborated in PDX models, affirming the translational validity of the chip-based findings and underlining the clinical potential of targeting KRAS-mutant CRC through metabolic and biomechanical pathways biology [104]. This evidence concerns the gene KRAS and colorectal carcinoma.